BC Extra | May 8, 2019
Company News

Management tracks: Immunocore, Kyn, Engitix

Immunocore Ltd. (Abingdon, U.K.) brought on a third ex-AstraZeneca plc (LSE:AZN; NYSE:AZN) executive, hiring Mohammed Dar as head of clinical development and CMO. Dar was VP, clinical development oncology, R&D at AZ's MedImmune LLC subsidiary....
BC Week In Review | Feb 17, 2017
Financial News

Miragen completes venture financing

MicroRNA company Miragen Therapeutics Inc. (Boulder, Colo.) raised $40.7 million in a private placement immediately prior to the close of its merger with publicly listed Signal Genetics Inc. on Feb. 13 to form Miragen Therapeutics...
BC Week In Review | Nov 3, 2016
Company News

Signal, miRagen deal

miRagen will merge with Signal to form a publicly traded microRNA company focused on hematological malignancies, pathological fibrosis and cardiovascular and neurodegenerative diseases. The surviving entity will retain miRagen's name and trade on NASDAQ. The...
BC Extra | Nov 1, 2016
Company News

miRagen finds public path via Signal merger

miRagen Therapeutics Inc. (Boulder, Colo.) will merge with Signal Genetics Inc. (NASDAQ:SGNL) to form a publicly traded microRNA company focused on hematological malignancies, pathological fibrosis and cardiovascular and neurodegenerative diseases. The surviving entity will retain...
BioCentury | Apr 6, 2015
Finance

Fundamental rally

2Q15 Financial Markets Preview Following three consecutive years of spectacular returns and a solid first quarter, bankers and buysiders remain confident that large caps will continue to deliver on sales and smaller companies will continue...
BC Week In Review | Mar 23, 2015
Financial News

Signal Genetics financial update

Signal Genetics Inc. (NASDAQ:SGNL), New York, N.Y.   Business: Pharmacogenetics, Diagnostic   Date announced: 2015-03-02   Note: Signal Genetics raised $1.3 million through the sale of 482,142 shares at $2.80 to cover the overallotment from...
BC Week In Review | Feb 23, 2015
Financial News

Signal Genetics Inc completes follow-on

Signal Genetics Inc . (NASDAQ:SGNL), New York, N.Y.   Business: Pharmacogenetics, Diagnostic   Date completed: 2015-02-17   Type: Follow-on   Raised: $9 million   Shares: 3.2 million   Price: $2.80   Shares after offering: 7 million...
BC Week In Review | Feb 2, 2015
Financial News

Signal Genetics amends follow-on

Signal Genetics Inc. (NASDAQ:SGNL), New York, N.Y.   Business: Pharmacogenetics, Diagnostic   Date announced: 2015-01-29   Type: Follow-on   To be raised: Up to $8.6 million   Shares: 2.9 million   Price prior: $3.22  ...
BC Week In Review | Jan 19, 2015
Financial News

Signal Genetics proposes follow-on

Signal Genetics Inc. (NASDAQ:SGNL), New York, N.Y.   Business: Pharmacogenetics, Diagnostic   Date announced: 2015-01-15   Type: Follow-on   To be raised: Up to $8.6 million   Shares: TBD   Price prior: $3.22   Underwriter:...
BC Week In Review | Jan 12, 2015
Company News

Signal Genetics management update

Signal Genetics Inc. (NASDAQ:SGNL), New York, N.Y.   Business: Pharmacogenetics, Diagnostic   Hired: Sudipto Sur as chief information officer, formerly president of Anssur Corp.  ...
Items per page:
1 - 10 of 37
BC Extra | May 8, 2019
Company News

Management tracks: Immunocore, Kyn, Engitix

Immunocore Ltd. (Abingdon, U.K.) brought on a third ex-AstraZeneca plc (LSE:AZN; NYSE:AZN) executive, hiring Mohammed Dar as head of clinical development and CMO. Dar was VP, clinical development oncology, R&D at AZ's MedImmune LLC subsidiary....
BC Week In Review | Feb 17, 2017
Financial News

Miragen completes venture financing

MicroRNA company Miragen Therapeutics Inc. (Boulder, Colo.) raised $40.7 million in a private placement immediately prior to the close of its merger with publicly listed Signal Genetics Inc. on Feb. 13 to form Miragen Therapeutics...
BC Week In Review | Nov 3, 2016
Company News

Signal, miRagen deal

miRagen will merge with Signal to form a publicly traded microRNA company focused on hematological malignancies, pathological fibrosis and cardiovascular and neurodegenerative diseases. The surviving entity will retain miRagen's name and trade on NASDAQ. The...
BC Extra | Nov 1, 2016
Company News

miRagen finds public path via Signal merger

miRagen Therapeutics Inc. (Boulder, Colo.) will merge with Signal Genetics Inc. (NASDAQ:SGNL) to form a publicly traded microRNA company focused on hematological malignancies, pathological fibrosis and cardiovascular and neurodegenerative diseases. The surviving entity will retain...
BioCentury | Apr 6, 2015
Finance

Fundamental rally

2Q15 Financial Markets Preview Following three consecutive years of spectacular returns and a solid first quarter, bankers and buysiders remain confident that large caps will continue to deliver on sales and smaller companies will continue...
BC Week In Review | Mar 23, 2015
Financial News

Signal Genetics financial update

Signal Genetics Inc. (NASDAQ:SGNL), New York, N.Y.   Business: Pharmacogenetics, Diagnostic   Date announced: 2015-03-02   Note: Signal Genetics raised $1.3 million through the sale of 482,142 shares at $2.80 to cover the overallotment from...
BC Week In Review | Feb 23, 2015
Financial News

Signal Genetics Inc completes follow-on

Signal Genetics Inc . (NASDAQ:SGNL), New York, N.Y.   Business: Pharmacogenetics, Diagnostic   Date completed: 2015-02-17   Type: Follow-on   Raised: $9 million   Shares: 3.2 million   Price: $2.80   Shares after offering: 7 million...
BC Week In Review | Feb 2, 2015
Financial News

Signal Genetics amends follow-on

Signal Genetics Inc. (NASDAQ:SGNL), New York, N.Y.   Business: Pharmacogenetics, Diagnostic   Date announced: 2015-01-29   Type: Follow-on   To be raised: Up to $8.6 million   Shares: 2.9 million   Price prior: $3.22  ...
BC Week In Review | Jan 19, 2015
Financial News

Signal Genetics proposes follow-on

Signal Genetics Inc. (NASDAQ:SGNL), New York, N.Y.   Business: Pharmacogenetics, Diagnostic   Date announced: 2015-01-15   Type: Follow-on   To be raised: Up to $8.6 million   Shares: TBD   Price prior: $3.22   Underwriter:...
BC Week In Review | Jan 12, 2015
Company News

Signal Genetics management update

Signal Genetics Inc. (NASDAQ:SGNL), New York, N.Y.   Business: Pharmacogenetics, Diagnostic   Hired: Sudipto Sur as chief information officer, formerly president of Anssur Corp.  ...
Items per page:
1 - 10 of 37